Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Abstract Text:

K Berger,F Hessel,J Kreuzer,A Smala,H C Diener,K Berger,F Hessel,J Kreuzer,A Smala,H C Diener,

OBJECTIVES: To model the 2-year cost-effectiveness of secondary prevention with clopidogrel versus aspirin (acetylsalicylic acid) (ASS) in German patients with myocardial infarction (MI), ischaemic stroke (IS) or diagnosed with peripheral arterial disease (PAD), based on CAPRIE trial data and from the perspective of German third party payers (TPP). METHODS: An existing Markov model was adapted to Germany by using German cost data. The model was extended by using different datasets for cardiovascular event survival times (Framingham vs. Saskatchewan health databases) and in two separate scenarios. RESULTS: The treatment with clopidogrel leads to a reduction of 13.19 vascular events per 1000 patients, of which 2.21 are vascular deaths. The overall incremental costs for the 2-year management of atherothrombotic patients with clopidogrel instead of ASS are calculated to be about euro1 241 440 per 1000 patients. The number of life-years saved (LYS) has been calculated as the difference in the number of life-years lost due to vascular death or events with ASS versus clopidogrel: it is 86.35 LYS when analysis is based on Framingham data and 66.07 LYS with Saskatchewan-based survival data. The incremental costs per LYS are euro14 380 and euro18 790, respectively. Cost-effectiveness is sensitive to changes in survival data, discounting and daily costs of clopidogrel, but stable against substantial (+/- 25%) changes in all other cost data. CONCLUSION: The findings for Germany are in line with published results for Belgium (euro13 390 per LYS) and also with results for Italy (euro17 500 per LYS), both based on Saskatchewan data, and with a French analysis based on Framingham data (euro15 907 per LYS). Even if no officially accepted cost-effectiveness threshold exists for Germany at present, incremental cost-effectiveness results of less than euro20 000 per LYS for the treatment with clopidogrel can be assumed to be acceptable for German third party payers.

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Publishing Authors By Initials

K Berger,F Hessel,J Kreuzer,A Smala,HC Diener,K Berger,F Hessel,J Kreuzer,A Smala,HC Diener,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Current medical research and opinion

VOLUME: 24

Page Numbers: 267-74

Journal Abbreviation:

ISSN: 1473-4877

DAY: 7

MONTH: Jan

YEAR: 2008

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 351014

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.

AFFILIATION: University Hospital Munich, Department of Hemostaseology and Transfusion Medicine, Economic Working Group, Ziemssenstrasse 1, D-80336 Munich, Germany. Karin.Berger@med.uni-muenchen.de

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Med Res Opin

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany Related Publications

• A personal view of the classification and definition of drug dependence headache.
• Antiplatelet agents and randomized trials.
• Ca( 2+ )-induced cl (-) efflux at rat distal colonic epithelium.
• Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
• Cortical activation in hemianopia after stroke.
• Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine.
• Effect of carbon dioxide, temperature, and relative humidity on production of aflatoxin in peanuts.
• Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms.
• How can PET scans help us understand headache mechanisms?
• Low-dose aspirin for migraine prophylaxis in women.
• Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo.
• Placebo in headache trials.
• RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.
• Saccade induced cortical activation in patients with post-stroke visual field defects.
• Se02 the validity of an integrated clinical simulator for learning laparoscopic appendicectomy.
• Stimulation of voltage-dependent Ca2+ channels by NO at rat myenteric neurons.
• Sumatriptan in the treatment of cluster headache.
• Sumatriptan: vasoactive effect on human dural vessels, demonstrated by subselective angiography.
• Systemic Risk Score Evaluation in Ischemic Stroke Patients (SCALA) : A prospective cross sectional study in 85 German stroke units.
• Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome?
• Use of almotriptan in triptan-experienced and triptan-naïve patients.
• [Abortion after the 12th completed pregnancy week. Report of experience of a specialist commission]
• [Development of a screening tool for migraine prophylaxis]
• [Incidence of hidden iron deficiency in women, especially in pregnancy and puerperium.]
• [Monitoring stroke units: management, outcome, efficiency]
• [On the applicability of vaginal cytology in the determination of delivery term and in the recognition of prolonged pregnancy]
• [Pathogenesis of anemia in myomas.]
• [Results in the management of pregnancies involving risk factors]
• [Serologic toxoplasmosis control in pregnancy using enzyme immunoassay (EIA). 1st experiences]
• [The change of cervical state during pregnancy (author's transl)]